Impact of Semaglutide in Liver Transplant Candidates with Obesity (SOMAL Study): A Prospective Randomized Study.
Key facts
- Where
- Murcia, SpanyolországSee the site
- Phase
- 3. fázis
Where in Spanyolország
- University Clinical Hospital Virgen De La ArrixacaMurcia, SpanyolországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
- Trial code
- EU 2026-526953-32-00
- Record updated
- 2026. október 2.
- Original description
To assess the efficacy and safety of semaglutide in liver transplant candidates in terms of weight loss and metabolic control.Read full original descriptionShow less
To assess the efficacy and safety of semaglutide in liver transplant candidates in terms of weight loss and metabolic control.
Inclusion: Age ≥ 18 years; Candidate for a liver transplant (on the active waiting list or being evaluated for inclusion on the list); Body Mass Index (BMI) ≥ 30 kg/m², or ≥ 27 kg/m² with at least one metabolic comorbidity (type 2 diabetes mellitus with HbA1c <8, high blood pressure, dyslipidaemia); Estimated time on the waiting list sufficient to complete at least 12 weeks of treatment with semaglutide prior to the transplant; The patient or their legal representative must sign the study’s informed consent form.
Exclusion: Having received prior treatment with semaglutide within the last 6 months; Plan for a multi-organ transplant (e.g. liver-kidney) or a re-transplant; Absolute contraindication to the use of GLP-1 receptor agonists (personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2); Upper gastrointestinal haemorrhage due to oesophageal varices; A history of acute or chronic pancreatitis; Severe disease-related malnutrition (according to GLIM criteria) or advanced sarcopenia (assessed by bioimpedance analysis: ASMMI: <5 in women and >7 in men); Haemodynamic instability or an active, uncontrolled infection; Advanced chronic kidney disease (GFR <30 mL/min/1.73 m²); Type 2 diabetes mellitus with HbA1c ≥8; Pregnancy or breastfeeding; Currently participating in, or having participated in, another clinical trial in the last 30 days; CHILD C liver dysfunction; Documented severe gastroparesis.